Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study of Olaparib and Estradiol in Advanced ER+ Breast Cancer (PHOEBE)

NCT05900895 is registered in ClinicalTrials.gov with Mary D Chamberlin as lead sponsor.

NCT NCT05900895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05900895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study of Olaparib and Estradiol in Advanced ER+ Breast Cancer (PHOEBE)
Lead sponsor
Mary D Chamberlin
Phase
Phase 1
Overall status
Recruiting
Start date
July 15, 2024
Completion date
December 31, 2028
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer